Cadrenal Therapeutics, Inc. · Drugmakers

CVKD

High riskNext report: Around Nov 9 (est.)

View price ↗

The short version

A company still losing money, with high risk. Institutions are adding.

Going well

No debt reported

Watch out for

About 4 months of cash left at its current burn
Losing money, losses are large next to sales
1 offering filing in 6 months (may sell new shares)

Money moves

No insider buying or selling in the last 30 days
Institutions added 27% to their holdings in the quarter ending June 2026 (12 bought, 7 sold)

Facts from SEC filings, not a recommendation.

The business over time

Last 12 quarters, from SEC filings

Profit, Jun '26

-$3.3M

Sep '23Tap a barJun '26

Last 12 months: -$11.5M.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

1/3Weak

PassDebt under half of equityNot relying on borrowed money.No debt reported
MissFree cash flow positiveBrings in more cash than it spends to run and grow.-$12.6M
MissShare count not growingNot diluting owners. Falling means buybacks.+1.1% in 3 years

Total debt: None; 0.00x equity
Current ratio: 2.72x; short-term assets / bills due
Free cash flow: -$12.6M

From annual reports filed with the SEC. Not in this company's SEC data, so not scored: return on equity 15%+, net margin 10%+, profitable every year, gross margin 40%+. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported Aug 13

EPS: -$1.14; vs -$1.87
Free cash flow: -$2.2M
Share count: +48.5%; vs a year ago

Insider rating

Last 90 days

No open-market insider buys or sells in the last 90 days.

Weekly insider trend

No trades to chart yet.

Filing buzz

Last 7 days vs normal

0/ 100

This week: 0
Normal week: 1.2
vs normal: 0.0x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Accumulating+27.0%

Institutions added 27.0% to their holdings. 12 bought, 7 sold.

Shares held by institutions114K

Sep '24Jun '26

Safety check

From SEC filings

Share count growthYearly rate, last 3 years

+39.7%

Cash runwayAt last year's cash burn

2 months

Debt to equityLatest balance sheet: debt compared with what owners have

No debt reported

Shares outstandingLatest reported

Why high risk

Losing money, losses are large next to sales
About 2 months of cash left at its current burn
Share count growing 39.7% a year (dilution)
3 offering filings in 6 months (may sell new shares)

Earnings reports

Last 12

Next reportAround Nov 9 (est.)Estimated from the same quarter last year

Results filedAug 13
Results filedMay 7
Results filedMar 31
Results filedNov 10, 2025
Results filedAug 11, 2025

Flags and big holders

Offerings 6 months, flags 12 months, holders 90 days

New 5%+ holder (passive)Aug 7 · View filing ↗Big holder Offering prospectusJul 20 · View filing ↗Offering Shelf offering registrationJul 13 · View filing ↗Offering Major agreementJul 1 · View filing ↗Offering

Insider trades

Open-market buys and sells, last 90 days

No open-market buys or sells in 90 days. Grants and option exercises are left out.

"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.

Latest filings

Straight from SEC EDGAR

Stock awardGlynn WilsonDirector

75,000 shares

Now owns 75,000 shares
Exercise price $0.91
Stock Option
Filed 4 days after trade

Oct 9Form 4 ↗

Stock awardJeffrey Scott ColeChief Operating Officer

150,000 shares

Now owns 150,000 shares
Exercise price $0.91
Stock Option
Filed 4 days after trade

Oct 9Form 4 ↗

Stock awardJohn Raymond MurphyDirector

75,000 shares

Now owns 75,000 shares
Exercise price $0.91
Stock Option
Filed 4 days after trade

Oct 9Form 4 ↗

Stock awardLee Scott GoldenDirector

75,000 shares

Now owns 75,000 shares
Exercise price $0.91
Stock Option
Filed 4 days after trade

Oct 9Form 4 ↗

Stock awardQuang X PhamChairman and CEO, Director, 10% owner

200,000 shares

Now owns 200,000 shares
Exercise price $0.91
Stock Option
Filed 4 days after trade

Oct 9Form 4 ↗

Employee stock plan registrationOct 8 · Form S-8 ↗Investor disclosureOct 7 · Form 8-K ↗Leadership changeSep 29 · Form 8-K ↗Employee stock plan registrationSep 3 · Form S-8 ↗Investor disclosureAug 31 · Form 8-K ↗Earnings resultsAug 13 · Form 8-K ↗Quarterly reportAug 13 · Form 10-Q ↗New 5%+ holder (passive)Aug 7 · Form SCHEDULE 13G ↗Proxy statementAug 3 · Form DEF 14A ↗ARSAug 3 · Form ARS ↗

Source: SEC EDGAR filings. For informational purposes. Not investment advice.

Report a problem with this page